The following attribute of a drug tends to reduce its volume of distribution: A. High lipid solubility B. Low ionisation at physiological pH values C. High plasma protein binding D. High tissue binding

The following attribute of a drug tends to reduce its
volume of distribution:
A. High lipid solubility
B. Low ionisation at physiological pH values
C. High plasma protein binding
D. High tissue binding
by

1 Answer

Answer :

C. High plasma protein binding
by

Related questions

The following attribute of a drug tends to reduce its volume of distribution: A. High lipid solubility B. Low ionisation at physiological pH values C. High plasma protein binding D. High tissue binding

Description : The following attribute of a drug tends to reduce its volume of distribution: A. High lipid solubility B. Low ionisation at physiological pH values C. High plasma protein binding D. High tissue binding

Last Answer : C. High plasma protein binding

The following attribute of a drug tends to reduce its volume of distribution: A. High lipid solubility B. Low ionisation at physiological pH values C. High plasma protein binding D. High tissue binding

Description : The following attribute of a drug tends to reduce its volume of distribution: A. High lipid solubility B. Low ionisation at physiological pH values C. High plasma protein binding D. High tissue binding

Last Answer : C. High plasma protein binding

If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Description : If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Last Answer : D. Total body clearanc

Glomerular filtration of a drug is affected by its: A. Lipid solubility B. Plasma protein binding C. Degree of ionization D. Rate of tubular secretion

Description : Glomerular filtration of a drug is affected by its: A. Lipid solubility B. Plasma protein binding C. Degree of ionization D. Rate of tubular secretion

Last Answer : B. Plasma protein binding

Glomerular filtration of a drug is affected by its: A. Lipid solubility B. Plasma protein binding C. Degree of ionization D. Rate of tubular secretion

Description : Glomerular filtration of a drug is affected by its: A. Lipid solubility B. Plasma protein binding C. Degree of ionization D. Rate of tubular secretion

Last Answer : B. Plasma protein binding

If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Description : If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Last Answer : D. Total body clearance

High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Description : High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Last Answer : D. Generally makes the drug long acting

High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Description : High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Last Answer : D. Generally makes the drug long acting

High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Description : High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Last Answer : D. Generally makes the drug long acting

A nonvolatile, highly lipid soluble drug is metabolized at a rate of 15% per hour. On intravenous injection it produces general anaesthesia for 10 min. Which process is responsible for termination of its action: A. Metabolism in liver B. Plasma protein binding C. Excretion by kidney D. Redistribution

Description : A nonvolatile, highly lipid soluble drug is metabolized at a rate of 15% per hour. On intravenous injection it produces general anaesthesia for 10 min. Which process is responsible for termination of ... : A. Metabolism in liver B. Plasma protein binding C. Excretion by kidney D. Redistribution

Last Answer : D. Redistribution

A nonvolatile, highly lipid soluble drug is metabolized at a rate of 15% per hour. On intravenous injection it produces general anaesthesia for 10 min. Which process is responsible for termination of its action: A. Metabolism in liver B. Plasma protein binding C. Excretion by kidney D. Redistribution

Description : A nonvolatile, highly lipid soluble drug is metabolized at a rate of 15% per hour. On intravenous injection it produces general anaesthesia for 10 min. Which process is responsible for termination of ... : A. Metabolism in liver B. Plasma protein binding C. Excretion by kidney D. Redistribution

Last Answer : D. Redistribution

The most important factor which governs diffusion of drugs across capillaries other than those in the brain is: A. Blood flow through the capillary B. Lipid solubility of the drug C. pKa value of the drug D. pH of the medium

Description : The most important factor which governs diffusion of drugs across capillaries other than those in the brain is: A. Blood flow through the capillary B. Lipid solubility of the drug C. pKa value of the drug D. pH of the medium

Last Answer : A. Blood flow through the capillary

The most important factor which governs diffusion of drugs across capillaries other than those in the brain is: A. Blood flow through the capillary B. Lipid solubility of the drug C. pKa value of the drug D. pH of the medium

Description : The most important factor which governs diffusion of drugs across capillaries other than those in the brain is: A. Blood flow through the capillary B. Lipid solubility of the drug C. pKa value of the drug D. pH of the medium

Last Answer : A. Blood flow through the capillary

The most important factor governing absorption of a drug from intact skin is: A. Molecular weight of the drug B. Site of application C. Lipid solubility of the drug D. Nature of the base used in the formulation

Description : The most important factor governing absorption of a drug from intact skin is: A. Molecular weight of the drug B. Site of application C. Lipid solubility of the drug D. Nature of the base used in the formulation

Last Answer : C. Lipid solubility of the drug

The most important factor governing absorption of a drug from intact skin is: A. Molecular weight of the drug B. Site of application C. Lipid solubility of the drug D. Nature of the base used in the formulation

Description : The most important factor governing absorption of a drug from intact skin is: A. Molecular weight of the drug B. Site of application C. Lipid solubility of the drug D. Nature of the base used in the formulation

Last Answer : C. Lipid solubility of the drug

The most important factor governing absorption of a drug from intact skin is: A. Molecular weight of the drug B. Site of application C. Lipid solubility of the drug D. Nature of the base used in the formulation

Description : The most important factor governing absorption of a drug from intact skin is: A. Molecular weight of the drug B. Site of application C. Lipid solubility of the drug D. Nature of the base used in the formulation

Last Answer : C. Lipid solubility of the drug

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

If the total amount of a drug present in the body at a given moment is 2.0 g and its plasma concentration is 25 μg/ml, its volume of distribution is: A. 100 L B. 80 L C. 60 L D. 50 L

Description : If the total amount of a drug present in the body at a given moment is 2.0 g and its plasma concentration is 25 μg/ml, its volume of distribution is: A. 100 L B. 80 L C. 60 L D. 50 L

Last Answer : B. 80 L

2 If the total amount of a drug present in the body at a given moment is 2.0 g and its plasma concentration is 25 μg/ml, its volume of distribution is: A. 100 L B. 80 L C. 60 L D. 50 L

Description : 2 If the total amount of a drug present in the body at a given moment is 2.0 g and its plasma concentration is 25 μg/ml, its volume of distribution is: A. 100 L B. 80 L C. 60 L D. 50 L

Last Answer : B. 80 L

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

If the total amount of a drug present in the body at a given moment is 2.0 g and its plasma concentration is 25 μ g/ml, its volume of distribution is: A. 100 L B. 80 L C. 60 L D. 50 L

Description : If the total amount of a drug present in the body at a given moment is 2.0 g and its plasma concentration is 25 μ g/ml, its volume of distribution is: A. 100 L B. 80 L C. 60 L D. 50 L

Last Answer : B. 80 L

Marked redistribution is a feature of: A. Highly lipid soluble drugs B. Poorly lipid soluble drugs C. Depot preparations D. Highly plasma protein bound drugs

Description : Marked redistribution is a feature of: A. Highly lipid soluble drugs B. Poorly lipid soluble drugs C. Depot preparations D. Highly plasma protein bound drugs

Last Answer : A. Highly lipid soluble drugs

Marked redistribution is a feature of: A. Highly lipid soluble drugs B. Poorly lipid soluble drugs C. Depot preparations D. Highly plasma protein bound drugs

Description : Marked redistribution is a feature of: A. Highly lipid soluble drugs B. Poorly lipid soluble drugs C. Depot preparations D. Highly plasma protein bound drugs

Last Answer : A. Highly lipid soluble drugs

Marked redistribution is a feature of: A. Highly lipid soluble drugs B. Poorly lipid soluble drugs C. Depot preparations D. Highly plasma protein bound drugs

Description : Marked redistribution is a feature of: A. Highly lipid soluble drugs B. Poorly lipid soluble drugs C. Depot preparations D. Highly plasma protein bound drugs

Last Answer : A. Highly lipid soluble drugs

The plasma half life of penicillin-G is longer in the new born because their: A. Plasma protein level is low B. Drug metabolizing enzymes are immature C. Glomerular filtration rate is low D. Tubular transport mechanisms are not well developed

Description : The plasma half life of penicillin-G is longer in the new born because their: A. Plasma protein level is low B. Drug metabolizing enzymes are immature C. Glomerular filtration rate is low D. Tubular transport mechanisms are not well developed

Last Answer : D. Tubular transport mechanisms are not well developed

Induction of drug metabolizing enzymes involves: A. A conformational change in the enzyme protein to favour binding of substrate molecules B. Expression of enzyme molecules on the surface of hepatocytes C. Enhanced transport of substrate molecules into hepatocytes D. Increased synthesis of enzyme protein

Description : Induction of drug metabolizing enzymes involves: A. A conformational change in the enzyme protein to favour binding of substrate molecules B. Expression of enzyme molecules on the surface of ... C. Enhanced transport of substrate molecules into hepatocytes D. Increased synthesis of enzyme protein

Last Answer : D. Increased synthesis of enzyme protein

Induction of drug metabolizing enzymes involves: A. A conformational change in the enzyme protein to favour binding of substrate molecules B. Expression of enzyme molecules on the surface of hepatocytes C. Enhanced transport of substrate molecules into hepatocytes D. Increased synthesis of enzyme protein

Description : Induction of drug metabolizing enzymes involves: A. A conformational change in the enzyme protein to favour binding of substrate molecules B. Expression of enzyme molecules on the surface of ... C. Enhanced transport of substrate molecules into hepatocytes D. Increased synthesis of enzyme protein

Last Answer : D. Increased synthesis of enzyme protein

5 A nonvolatile, highly lipid soluble drug is metabolized at a rate of 15% per hour. On intravenous injection it produces general anaesthesia for 10 min. Which process is responsible for termination of its action: A. Metabolism in liver B. Plasma protein binding C. Excretion by kidney D. Redistribution

Description : 5 A nonvolatile, highly lipid soluble drug is metabolized at a rate of 15% per hour. On intravenous injection it produces general anaesthesia for 10 min. Which process is responsible for termination ... : A. Metabolism in liver B. Plasma protein binding C. Excretion by kidney D. Redistribution

Last Answer : D. Redistribution

Which of the following is not a primary/fundamental, but a derived pharmacokinetic parameter: A. Bioavailability B. Volume of distribution C. Clearance D. Plasma half life

Description : Which of the following is not a primary/fundamental, but a derived pharmacokinetic parameter: A. Bioavailability B. Volume of distribution C. Clearance D. Plasma half life

Last Answer : D. Plasma half life

The plasma protein bound fraction of a drug: A. Contributes to the response at the given moment B. Remains constant irrespective of the total drug concentration C. Remains constant irrespective of the disease state D. Is not available for metabolism unless actively extracted by the liver

Description : The plasma protein bound fraction of a drug: A. Contributes to the response at the given moment B. Remains constant irrespective of the total drug concentration C. Remains constant irrespective of the disease state D. Is not available for metabolism unless actively extracted by the liver

Last Answer : D. Is not available for metabolism unless actively extracted by the liver

The plasma protein bound fraction of a drug: A. Contributes to the response at the given moment B. Remains constant irrespective of the total drug concentration C. Remains constant irrespective of the disease state D. Is not available for metabolism unless actively extracted by the liver

Description : The plasma protein bound fraction of a drug: A. Contributes to the response at the given moment B. Remains constant irrespective of the total drug concentration C. Remains constant irrespective of the disease state D. Is not available for metabolism unless actively extracted by the liver

Last Answer : D. Is not available for metabolism unless actively extracted by the liver

The plasma protein bound fraction of a drug: A. Contributes to the response at the given moment B. Remains constant irrespective of the total drug concentration C. Remains constant irrespective of the disease state D. Is not available for metabolism unless actively extracted by the liver

Description : The plasma protein bound fraction of a drug: A. Contributes to the response at the given moment B. Remains constant irrespective of the total drug concentration C. Remains constant irrespective of the disease state D. Is not available for metabolism unless actively extracted by the liver

Last Answer : D. Is not available for metabolism unless actively extracted by the liver

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

Which of the following is not true of the blood-brain barrier: A. It is constituted by tight junctions between the endothelial cells of brain capillaries and the glial tissue B. It allows passage of lipid soluble drugs into the brain C. It limits entry of highly ionized drugs into the brain D. It regulates passage of substances from brain into blood

Description : Which of the following is not true of the blood-brain barrier: A. It is constituted by tight junctions between the endothelial cells of brain capillaries and the glial tissue B. It allows passage ... of highly ionized drugs into the brain D. It regulates passage of substances from brain into blood

Last Answer : D. It regulates passage of substances from brain into blood

Which of the following is not true of the blood-brain barrier: A. It is constituted by tight junctions between the endothelial cells of brain capillaries and the glial tissue B. It allows passage of lipid soluble drugs into the brain C. It limits entry of highly ionized drugs into the brain D. It regulates passage of substances from brain into blood

Description : Which of the following is not true of the blood-brain barrier: A. It is constituted by tight junctions between the endothelial cells of brain capillaries and the glial tissue B. It allows passage ... of highly ionized drugs into the brain D. It regulates passage of substances from brain into blood

Last Answer : D. It regulates passage of substances from brain into blood

Biotransformation of drugs is primarily directed to: A. Activate the drug B. Inactivate the drug C. Convert lipid soluble drugs into nonlipid soluble metabolites D. Convert nonlipid soluble drugs into lipid soluble metabolites

Description : Biotransformation of drugs is primarily directed to: A. Activate the drug B. Inactivate the drug C. Convert lipid soluble drugs into nonlipid soluble metabolites D. Convert nonlipid soluble drugs into lipid soluble metabolites

Last Answer : C. Convert lipid soluble drugs into nonlipid soluble metabolites

Biotransformation of drugs is primarily directed to: A. Activate the drug B. Inactivate the drug C. Convert lipid soluble drugs into nonlipid soluble metabolites D. Convert nonlipid soluble drugs into lipid soluble metabolites

Description : Biotransformation of drugs is primarily directed to: A. Activate the drug B. Inactivate the drug C. Convert lipid soluble drugs into nonlipid soluble metabolites D. Convert nonlipid soluble drugs into lipid soluble metabolites

Last Answer : C. Convert lipid soluble drugs into nonlipid soluble metabolites

Transdermal drug delivery systems offer the following advantages except: A. They produce high peak plasma concentration of the drug B. They produce smooth and nonfluctuating plasma concentration of the drug C. They minimise interindividual variations in the achieved plasma drug concentration D. They avoid hepatic first-pass metabolism of the drug

Description : Transdermal drug delivery systems offer the following advantages except: A. They produce high peak plasma concentration of the drug B. They produce smooth and nonfluctuating plasma concentration of the ... the achieved plasma drug concentration D. They avoid hepatic first-pass metabolism of the drug

Last Answer : A. They produce high peak plasma concentration of the drug

Transdermal drug delivery systems offer the following advantages except: A. They produce high peak plasma concentration of the drug B. They produce smooth and nonfluctuating plasma concentration of the drug C. They minimise interindividual variations in the achieved plasma drug concentration D. They avoid hepatic first-pass metabolism of the drug

Description : Transdermal drug delivery systems offer the following advantages except: A. They produce high peak plasma concentration of the drug B. They produce smooth and nonfluctuating plasma concentration of the ... the achieved plasma drug concentration D. They avoid hepatic first-pass metabolism of the drug

Last Answer : A

If a drug is excreted in urine at the rate of 10 mg/hr at a steady-state plasma concentration of 5 mg/L, then its renal clearance is: A. 0.5 L/hr B. 2.0 L/hr C. 5.0 L/hr D. 20 L/hr

Description : If a drug is excreted in urine at the rate of 10 mg/hr at a steady-state plasma concentration of 5 mg/L, then its renal clearance is: A. 0.5 L/hr B. 2.0 L/hr C. 5.0 L/hr D. 20 L/hr

Last Answer : B. 2.0 L/hr

When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Description : When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Last Answer : B. 4–5 half lives

If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Description : If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Last Answer : B. × 2

Sustained/controlled release oral dosage form is appropriate for the following type of drug: A. An antiarthritic with a plasma half life of 24 hr B. A sleep inducing hypnotic with a plasma half life of 2 hours C. An antihypertensive with a plasma half life of 3 hours D. An analgesic with a plasma half life of 6 hours used for relief of casual headache

Description : Sustained/controlled release oral dosage form is appropriate for the following type of drug: A. An antiarthritic with a plasma half life of 24 hr B. A sleep inducing hypnotic with a plasma half life of ... 3 hours D. An analgesic with a plasma half life of 6 hours used for relief of casual headache

Last Answer : Microsomal enzyme induction has one of the following features: A. Takes about one week to develop B. Results in increased affinity of the enzyme for the substrate C. It is irreversible D. Can be used to treat acute drug poisonings

Monitoring plasma drug concentration is useful while using: A. Antihypertensive drugs B. Levodopa C. Lithium carbonate D. MAO inhibitors

Description : Monitoring plasma drug concentration is useful while using: A. Antihypertensive drugs B. Levodopa C. Lithium carbonate D. MAO inhibitors

Last Answer : C. Lithium carbonate

When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Description : When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Last Answer : B. 4–5 half lives

If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Description : If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Last Answer : B. × 2

The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Description : The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Last Answer : B. Chemical antagonism

The antagonism between adrenaline and histamine is called ‘physiological antagonism’ because: A. Both are physiologically present in the body B. They act on physiological receptors C. Both affect many physiological processes D. They have opposite physiological effects

Description : The antagonism between adrenaline and histamine is called ‘physiological antagonism’ because: A. Both are physiologically present in the body B. They act on physiological receptors C. Both affect many physiological processes D. They have opposite physiological effects

Last Answer : D. They have opposite physiological effects

The dose of the following class of drugs has to be adjusted by repeated measurement of the affected physiological parameter: A. Oral contraceptives B. Antiepileptics C. Antidepressants D. Oral anticoagulants

Description : The dose of the following class of drugs has to be adjusted by repeated measurement of the affected physiological parameter: A. Oral contraceptives B. Antiepileptics C. Antidepressants D. Oral anticoagulants

Last Answer : D. Oral anticoagulants